Previous 10 | Next 10 |
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nath...
Entrada Therapeutics press release ( NASDAQ: TRDA ): Q2 GAAP EPS of -$0.74 misses by $0.02 . Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021. For further details see: ...
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244 million in cash, cash equivalents and marketable securities as of June 30, 2022 ...
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome measures and endpoints for clinical trials Entrada recently announced new preclinica...
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appoi...
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the ...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Gainers: USA Truck USAK +111%. ToughBuilt Industries TBLT +58%. Zendesk ZEN +29%. Femasys (FEMY) +30%. Chimerix CMRX +25%. Wrap Technologies (WRAP) +26%. Moving iMage Technologies MITQ +18%. TRACON Pharmaceuticals TCON +18%. LogicMark (LGMK) +16%. Zhong Yang Fina...
Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%. Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...
News, Short Squeeze, Breakout and More Instantly...
Entrada Therapeutics Inc. Company Name:
TRDA Stock Symbol:
NASDAQ Market:
Entrada Therapeutics Inc. Website:
2024-06-25 08:00:07 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $18.00 for TRDA on 2024-06-25 06:24:00. The adjusted price target was set to $18.00. At the time of the announcement, TRDA was trading at $14.24. TRDA currently trades -33.80% versus ...
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today an...
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments – – ENTR-601-44 demonstrat...